Use of PCV2-commercial vaccines in conventional swine herds: the impact on production parameters, viral load, rate of co-agent and viral mutation rate

• Grant number: 15/07994-7
• Support Opportunities: Regular Research Grants
• Start date: November 01, 2016
• End date: April 30, 2019
• Field of knowledge: Agronomical Sciences - Veterinary Medicine - Preventive Veterinary Medicine
• Principal Investigator: Alessandra Marnie Martins Gomes de Castro
• Grantee: Alessandra Marnie Martins Gomes de Castro
• Host Institution: Pró-Reitoria de Pós-Graduação. Centro Universitário das Faculdades Metropolitanas Unidas (UniFMU). São Paulo , SP, Brazil

Abstract

Porcine circovirus 2 is the primary causal agent of several syndromes that are collectively designated circovirose in Brazil. Worldwide, this virus is responsible for huge economic losses and it is assumed that prevention is a key point in the fight against the losses triggered by PCV2. Prior to the development of vaccines against PCV2 control measures focused on minimizing and / or eliminating the risk factors involved in their progression. Currently, there are several commercial vaccines available, which some of them are commercialized Brazil since 2008. Studies in other countries have shown the vaccine conferred immunity against the two genotypes commonly found (PCV2b and PCV2a), drastically reduce mortality and increase the performance of PCV2-infected animals. This project aims to determine the impact of the introduction of three commercial vaccines in PCV2-positive swine herds. Four hundred animals with 14 ± 2 days old will be selected, identified and distributed in one of four experimental groups (A, B, C, control). The vaccine will be administered at 21 ± 2 days of age; and serum and fecal samples will be collected from 20 animals in each group (A, B, C, control) one week before the vaccination (DPV-7), on the day of vaccination (DPV0), every 14 days until animals reached D56 and then, every 21 or 28 days (depend on the farm slaughter weight) until the end of the experiment. The animals will be weighed as the management of the farm, with at least three weighing during the experimental period, with the first on the DPV0. The samples will be submitted to the quantitative chain reaction by quantitative polymerase (qPCR) (serum and feces) and indirect ELISA with capture antibody (serum) for PCV2. Additionally, samples will be sequenced for the mutation rate for the comparison between vaccinated groups and the unvaccinated group. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

D.F. SILVA; V.H. SILVA; L.M. BARROS; T.S. OLIVEIRA; C.I.S. MACEDO; R.G. MESQUITA; A.R. SILVESTRINI; I.R. SILVESTRINI; S. FERRAZ; A.M.M.G. CASTRO. Vaccination strategies to curb environmental spread of Porcine Circovirus 2. SOUTH AFRICAN JOURNAL OF ANIMAL SCIENCE, v. 54, n. 4, p. 503-508, 2024-00-00. (15/07994-7)